Literature DB >> 355602

Baclofen in Parkinson's disease.

A J Lees, K M Shaw, G M Stern.   

Abstract

In a controlled trial, baclofen (mean dose 45 mg daily) signficantly increased disability from Parkinsonism in 12 patients with the long-term levodopa syndrome. Peak dose choreoathetosis was not improved but benefit was observed in all four patients with "off period dystonia." Adverse side effects were common and severe, and included visual hallucinations, vomiting, and dizziness.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 355602      PMCID： PMC1083385          DOI： 10.1136/jnnp.41.8.707

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  11 in total

1.  The action of baclofen on neurons of the substantia nigra and of the ventral tegmental area.

Authors:  H R Olpe; W P Koella; P Wolf; H L Haas
Journal:  Brain Res       Date:  1977-10-14       Impact factor: 3.252

2.  Baclofen treatment in chronic schizophrenia: a clinical trial.

Authors:  L B Bigelow; H Nasrallah; J Carman; J C Gillin; R J Wyatt
Journal:  Am J Psychiatry       Date:  1977-03       Impact factor: 18.112

3.  Letter: G.A.B.A. and Huntington's chorea.

Authors:  A Barbeau
Journal:  Lancet       Date:  1973-12-29       Impact factor: 79.321

4.  The action of beta-phenyl-GABA derivatives on neurones of the cat cerebral cortex.

Authors:  J Davies; J C Watkins
Journal:  Brain Res       Date:  1974-04-26       Impact factor: 3.252

5.  Effect of baclofen on cerebrospinal-fluid levels of 5-hydroxyindoleacetic acid and homovanillic acid.

Authors:  J Walinder; L Wallin; A Carlsson
Journal:  N Engl J Med       Date:  1977-02-24       Impact factor: 91.245

6.  Letter: Baclofen in the treatment of schizophrenia.

Authors:  P K Frederiksen
Journal:  Lancet       Date:  1975-03-22       Impact factor: 79.321

7.  "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease.

Authors:  A J Lees; K M Shaw; G M Stern
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

8.  The relationship between parkinsonism and tardive dyskinesia.

Authors:  J Gerlach
Journal:  Am J Psychiatry       Date:  1977-07       Impact factor: 18.112

9.  Biochemical effects of baclofen (beta-parachlorophenyl-GABA) on the dopamine and the noradrenaline in the rat brain.

Authors:  N E Andén; H Wachtel
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1977-02

10.  Baclofen (Lioresal) in the treatment ofneuroleptic-induced tardive dyskinesia.

Authors:  S Korsgaard
Journal:  Acta Psychiatr Scand       Date:  1976-07       Impact factor: 6.392
View more
  9 in total

1.  Gamma-aminobutyric acid(B) receptor activation suppresses stimulus-evoked burst firing in rat substantia nigra reticulata neurons.

Authors:  Ke-Zhong Shen; Steven W Johnson
Journal:  Neuroreport       Date:  2012-01-04       Impact factor: 1.837

Review 2.  Aetiology and natural history of Parkinson's disease.

Authors:  J M Pearce
Journal:  Br Med J       Date:  1978-12-16

3.  Tiapride in levodopa-induced involuntary movements.

Authors:  A J Lees; C M Lander; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1979-04       Impact factor: 10.154

Review 4.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

5.  CSF and plasma GABA levels in Parkinson's disease.

Authors:  R J Abbott; I F Pye; S R Nahorski
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-03       Impact factor: 10.154

Review 6.  Parkinson's disease treatment: past, present, and future.

Authors:  John D Elsworth
Journal:  J Neural Transm (Vienna)       Date:  2020-03-14       Impact factor: 3.575

7.  Pain in Parkinson's Disease.

Authors:  Jacob I. Sage
Journal:  Curr Treat Options Neurol       Date:  2004-05       Impact factor: 3.598

Review 8.  Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors?

Authors:  G Linazasoro; N Van Blercom; L Ugedo; J A Ruiz Ortega
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

Review 9.  The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective.

Authors:  Renaud de Beaurepaire; Julia M A Sinclair; Mathis Heydtmann; Giovanni Addolorato; Henri-Jean Aubin; Esther M Beraha; Fabio Caputo; Jonathan D Chick; Patrick de La Selle; Nicolas Franchitto; James C Garbutt; Paul S Haber; Philippe Jaury; Anne R Lingford-Hughes; Kirsten C Morley; Christian A Müller; Lynn Owens; Adam Pastor; Louise M Paterson; Fanny Pélissier; Benjamin Rolland; Amanda Stafford; Andrew Thompson; Wim van den Brink; Lorenzo Leggio; Roberta Agabio
Journal:  Front Psychiatry       Date:  2019-01-04       Impact factor: 4.157
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.